Cigna Corporation

The Cigna Group (Cigna Corporation) — company profile

Overview. Cigna Corporation, now operating as The Cigna Group (NYSE: CI), is a publicly traded global health-services company headquartered at 900 Cottage Grove Road, Bloomfield, Connecticut. Its corporate lineage traces to the Insurance Company of North America (1792), with the Cigna name adopted after the 1982 INA–Connecticut General merger. It is a large-cap company: recent public filings and financial data providers put FY2025 revenue at roughly $275 billion, net income near $6 billion, and headcount in the ~67,700–73,500 band. It is not a subsidiary of another company.

Operations. Cigna operates two reportable segments. Evernorth Health Services is its health-services arm — pharmacy benefit management (Express Scripts, acquired 2018), specialty pharmacy (Accredo), care delivery and benefit-management/analytics services sold to employers, insurers and government programs. Cigna Healthcare comprises U.S. Healthcare (commercial, group and individual medical, dental, behavioral and pharmacy benefits) and International Health, which sells health, life and accident coverage abroad. The company has narrowed scope over the past several years, selling its U.S. group life, accident and disability business to New York Life (2020) and agreeing to divest its Medicare Advantage business to HCSC.

Litigation posture. Cigna is an operating company, not a non-practicing entity and not a patent holder pressing infringement claims. The tracked docket shows 1 case as plaintiff, 0 as defendant, and that sole matter is an antitrust action rather than a patent-infringement suit. Cigna appears in patent-litigation databases because its claims rest on allegations about a drugmaker's patents, not because it enforces patents itself. No NPE or shell-licensor characteristics apply.

Notable case. Cigna Corporation v. Celgene Corporation (D.N.J., No. 2:21-cv-11686) was filed January 8, 2021 in the Eastern District of Pennsylvania and transferred by joint motion to the District of New Jersey, where related insurer suits (Humana, UnitedHealth, BCBSM) were consolidated before Judge Esther Salas. Cigna alleges Celgene and parent Bristol-Myers Squibb monopolized Thalomid and Revlimid through REMS manipulation, fraudulently obtained patents, sham infringement litigation and reverse-payment settlements with generics. Cigna is represented by Lowey Dannenberg P.C. Cigna filed a related pomalidomide (Pomalyst) action against Celgene/BMS in S.D.N.Y. in June 2025.